X001

Phase:
I
Status:
Completed
Strategies:
Protein
Candidates:
CN54gp140 mixed with GLA-AF
Countries:
United Kingdom
Volunteers:
12
Partners:
IAVI; Imperial College; Wellcome Trust; National Institute for Health Research, United Kingdom.
 

A Phase 1 Open-Labelled Trial to Evaluate the Safety and Immunogenicity of CN54gp140 in HIV-Uninfected, Healthy Volunteers.
ClinicalTrials.gov Identifier: NCT01966900